Beyond systemic metabolic regulation, accumulating studies indicate that SGLT2 inhibition may also confer hepatoprotective effects by ameliorating insulin resistance [20], attenuating hepatic steatosis, and modulating inflammatory pathways [21]. Here, SLC5A2 is linked to fatty liver disease.